Develops partial epigenetic reprogramming medicines using OSK transcription factors to restore aged cells toward a younger state.
Longevity biotech pursuing cellular reprogramming, autophagy, and plasma-based approaches to add healthy years to human lifespan.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →